Latest Shengtai Pharmaceut (SGTI) Headlines Cha
Post# of 4
Posted On: 03/11/2014 8:22:21 AM
Latest Shengtai Pharmaceut (SGTI) Headlines
Charles Frischer, James Sight and the Libby Frischer Family Partnership, LP Sends the Board of Directors of Shengtai Pharmaceutical, Inc. the Following Letter
Business Wire - Tue Sep 17, 7:00AM CDT
Charles Frischer, James Sight and the Libby Frischer Family Partnership, LP believes the Board of Directors at Shengtai Pharmaceutical, Inc. has recently taken actions which are not in the best interest of all shareholders. We also believe that Mr. Liu's efforts to take the company private could be assisted if the current public shareholders provided a portion of the financing for this proposed transaction. The attached letter more fully outlines our objectives.
Shengtai Pharmaceutical, Inc. Chairman Withdraws Preliminary Offer to Take Company Private and Dissolves Special Committee
PR Newswire - Wed Aug 07, 1:50AM CDT
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today announced that the Special Committee of its Board of Directors received a letter from its Chairman, Mr. Qingtai Liu ("Mr. Liu") on July 24, 2013 informing it that because he had been unsuccessful in obtaining financing to fund the acquisition of all the outstanding shares of common stock of the Company not currently owned by him and his affiliates in a going-private transaction for cash consideration of $1.65 per share (the "Proposal"), he had decided to withdraw the Proposal immediately and would file an amendment to the Schedule 13D/A previously filed on March 25, 2013.
Survey of Glucose in China
M2 - Wed May 22, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dd58h7/survey_of_glucose) has announced the addition of the "Survey of Glucose in China" report to their offering. After years of development, glucose has become one of the major starch sugars in China. However, in the past few years, China's glucose production has been expanding slowly, affected by weak demand and fierce competition. Furthermore, the price of glucose's raw material witnessed an uptrend in the same period. With the weak demand and high raw material costs, competition in China's glucose market is becoming increasingly intense. What has happened in the glucose market? How is the current competition structure of glucose in China? Who are the leading producers? What is the future relationship between supply and demand in the glucose market? With the application of glucose is quite wide in China due to its long history, what is the current consumption pattern of glucose in China? How will glucose's major downstream industries dev
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results
PR Newswire - Wed May 15, 9:00PM CDT
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended March 31, 2013.
Corn Products China News 2013 - 3rd Edition
M2 - Tue Apr 23, 5:02AM CDT
Research and Markets has announced the addition of the Corn Products China News 2013 - 03 report to their offering. In March 2013, domestic market price of corn witnessed a downtrend after it kept stable in Feb. 2013 because quantities of new and lower-quality corn in Northeast China was put into market. Farmers are urgent to sell their corn when the temperature is getting higher and it is more difficult for the storage of new corn with moisture. In addition, it is the first time that domestic market price of corn has experienced a downtrend during the temporary purchase period. Due to the increasing supply of corn, it is predicted domestic market price of corn will see a downtrend in April 2013 when the 2012/2013 temporary purchase of corn will end. Due to the fact that the market price of live pigs speeded up its downtrend in March 2013, the prices of most corn products as feed or feed additives decreased, including lysine, threonine, distillers dried grains with solubles, corn gluten meal, etc. Moreover, starch sugar and sugar alcohol welcomed their off consumption season. As a result, most corn products witnessed a stable or decreasing market price in March 2013 and the trend will last till April. Key Topics Covered: - Domestic import volume of DDGS up 41.3% in 2012 over 2011 - Chinese corn products Imp. & Exp. analysis in Jan. 2013 - Market price of furfural increases during Feb.-March 2013 - Domestic market price of edible ethanol decreases in the past five months - Shengtai Pharmaceutical: gross profit up while net profit down in H2 2012 - Baolingbao approved to issue new non-public stocks - Luzhou Bio-chem performs poorly in 2012 - Fufeng Group adopts aggressive low-price strategy towards minority amino acids market - Chinese government may strengthen elimination of backward capacities in 2013 - NPC deputies require more rights for private enterprises in cellulose ethanol industry - 2012/2013 outlook for corn market in China - China continues to levy anti-dumping duty on potato starch from the EU Companies Mentioned - Baolingbao Biology Co., Ltd. - CSPC Pharmaceutical Group Limited - Fufeng Group Co., Ltd. - Luzhou Bio-chem Technology Limited - Shengtai Pharmaceutical Inc. For more information visit Corn Products China News 2013 - 03
Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 14, 8:18PM CST
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended December 31, 2012.
Charles Frischer, James Sight and the Libby Frischer Family Partnership, LP Sends the Board of Directors of Shengtai Pharmaceutical, Inc. the Following Letter
Business Wire - Tue Sep 17, 7:00AM CDT
Charles Frischer, James Sight and the Libby Frischer Family Partnership, LP believes the Board of Directors at Shengtai Pharmaceutical, Inc. has recently taken actions which are not in the best interest of all shareholders. We also believe that Mr. Liu's efforts to take the company private could be assisted if the current public shareholders provided a portion of the financing for this proposed transaction. The attached letter more fully outlines our objectives.
Shengtai Pharmaceutical, Inc. Chairman Withdraws Preliminary Offer to Take Company Private and Dissolves Special Committee
PR Newswire - Wed Aug 07, 1:50AM CDT
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today announced that the Special Committee of its Board of Directors received a letter from its Chairman, Mr. Qingtai Liu ("Mr. Liu") on July 24, 2013 informing it that because he had been unsuccessful in obtaining financing to fund the acquisition of all the outstanding shares of common stock of the Company not currently owned by him and his affiliates in a going-private transaction for cash consideration of $1.65 per share (the "Proposal"), he had decided to withdraw the Proposal immediately and would file an amendment to the Schedule 13D/A previously filed on March 25, 2013.
Survey of Glucose in China
M2 - Wed May 22, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dd58h7/survey_of_glucose) has announced the addition of the "Survey of Glucose in China" report to their offering. After years of development, glucose has become one of the major starch sugars in China. However, in the past few years, China's glucose production has been expanding slowly, affected by weak demand and fierce competition. Furthermore, the price of glucose's raw material witnessed an uptrend in the same period. With the weak demand and high raw material costs, competition in China's glucose market is becoming increasingly intense. What has happened in the glucose market? How is the current competition structure of glucose in China? Who are the leading producers? What is the future relationship between supply and demand in the glucose market? With the application of glucose is quite wide in China due to its long history, what is the current consumption pattern of glucose in China? How will glucose's major downstream industries dev
Shengtai Pharmaceutical, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results
PR Newswire - Wed May 15, 9:00PM CDT
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended March 31, 2013.
Corn Products China News 2013 - 3rd Edition
M2 - Tue Apr 23, 5:02AM CDT
Research and Markets has announced the addition of the Corn Products China News 2013 - 03 report to their offering. In March 2013, domestic market price of corn witnessed a downtrend after it kept stable in Feb. 2013 because quantities of new and lower-quality corn in Northeast China was put into market. Farmers are urgent to sell their corn when the temperature is getting higher and it is more difficult for the storage of new corn with moisture. In addition, it is the first time that domestic market price of corn has experienced a downtrend during the temporary purchase period. Due to the increasing supply of corn, it is predicted domestic market price of corn will see a downtrend in April 2013 when the 2012/2013 temporary purchase of corn will end. Due to the fact that the market price of live pigs speeded up its downtrend in March 2013, the prices of most corn products as feed or feed additives decreased, including lysine, threonine, distillers dried grains with solubles, corn gluten meal, etc. Moreover, starch sugar and sugar alcohol welcomed their off consumption season. As a result, most corn products witnessed a stable or decreasing market price in March 2013 and the trend will last till April. Key Topics Covered: - Domestic import volume of DDGS up 41.3% in 2012 over 2011 - Chinese corn products Imp. & Exp. analysis in Jan. 2013 - Market price of furfural increases during Feb.-March 2013 - Domestic market price of edible ethanol decreases in the past five months - Shengtai Pharmaceutical: gross profit up while net profit down in H2 2012 - Baolingbao approved to issue new non-public stocks - Luzhou Bio-chem performs poorly in 2012 - Fufeng Group adopts aggressive low-price strategy towards minority amino acids market - Chinese government may strengthen elimination of backward capacities in 2013 - NPC deputies require more rights for private enterprises in cellulose ethanol industry - 2012/2013 outlook for corn market in China - China continues to levy anti-dumping duty on potato starch from the EU Companies Mentioned - Baolingbao Biology Co., Ltd. - CSPC Pharmaceutical Group Limited - Fufeng Group Co., Ltd. - Luzhou Bio-chem Technology Limited - Shengtai Pharmaceutical Inc. For more information visit Corn Products China News 2013 - 03
Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal Year 2013 Financial Results
PR Newswire - Thu Feb 14, 8:18PM CST
Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) (''Shengtai'' or ''the Company'' or "We" or "Us" or "Our"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the three months ended December 31, 2012.
(0)
(0)Shengtai Pharmaceut (SGTI) Stock Research Links
Scroll down for more posts ▼